Why Do B Cell Lymphoma Fail to Elicit Clinically Sufficient T Cell Immune Responses?

References

• Eisen H.N., Sakato N., Hall S.J. Myeloma proteins as tumor-specific antigens. Transplant. Proc. 1975; 7: 209–214
   PubMed Web of Science ®Google Scholar
• Janeway C.A., Jr., Sakato N., Eisen H.N. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc. Natl. Acad. Sci. USA 1975; 72: 2357–2360
   PubMed Web of Science ®Google Scholar
• Smith M.E., Holgate C.S., Williamson J.M., Grigor I., Quirke P., Bird C.C. Major histocompatibility complex class II antigen expression in B and T cell non-Hodgkin's lymphoma. J. Clin. Pathol. 1987; 40: 34–41
   PubMed Web of Science ®Google Scholar
• Moller P., Herrmann B., Moldenhauer G., Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Inn. J. Cancer 1987; 40: 32–39
   PubMed Web of Science ®Google Scholar
• Freedman A.S., Nadler L.M. Immunologic markers in non-Hodgkin's lymphoma. Hematol. Oncol. Clin. North. Am. 1991; 5: 871–889
   PubMed Web of Science ®Google Scholar
• Schultze J.L., Cardoso A.A., Freeman G.J., Seamon M.J., Daley J., Pinkus G.S., Gribben J.G., Nadler L.M. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA 1995; 92: 8200–8204
   PubMed Web of Science ®Google Scholar
• Longo D.L. Lymphoma. Curr. Opin. Oncol. 1997; 9: 389–391
   PubMedGoogle Scholar
• Bogen B., Malissen B., Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 1986; 16: 1373–1378
   PubMed Web of Science ®Google Scholar
• Campbell M.J., Carroll W., Kon S., Thielemans K., Rothbard J.B., Levy S.L. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol. 1987; 139: 2825–2833
   PubMed Web of Science ®Google Scholar
• Lauritzsen G.F., Weiss S., Dembic Z., Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. USA 1994; 91: 5700–5704
   PubMed Web of Science ®Google Scholar
• Levitsky H.I., Montgomery J., Ahmadzadeh M., Staveley-O'Carroll K., Guarnieri F., Longo D.L., Kwak L.W. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7–1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol. 1996; 156: 3858–3865
   PubMed Web of Science ®Google Scholar
• Kwak L.W., Young H.A., Pennington R.W., Weeks S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 1996; 93: 10972–10977
   PubMed Web of Science ®Google Scholar
• Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 1992; 327: 1209–1215
   PubMed Web of Science ®Google Scholar
• Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996; 2: 52–58
   PubMed Web of Science ®Google Scholar
• Nelson E.L., Li X., Hsu F.J., Kwak L.W., Levy R., Clayberger C., Krensky A.M. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996; 88: 580–589
   PubMed Web of Science ®Google Scholar
• Chen L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 1998; 19: 27–30
   PubMedGoogle Scholar
• Miller J.F., Heath W.R. Self-ignorance in the peripheral T-cell pool. Immunol. Rev. 1993; 133: 131–150
   PubMed Web of Science ®Google Scholar
• Guinan E.C., Gribben J.G., Boussiotis V.A., Freeman G.J., Nadler L.M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261–3282
   PubMed Web of Science ®Google Scholar
• Schultze J.L., Nadler L.M., Gribben J.G. B7-mediated costimulation and the immune response. Blood. Rev. 1996; 10: 111–127
   PubMed Web of Science ®Google Scholar
• Levitsky H.I. Tumors derived from antigen presenting cells. Semin. Immunol. 1996; 8: 281–287
   PubMedGoogle Scholar
• Sotomayor E.M., Borrello I., Levitsky H.I. Tolerance and cancer: a critical issue in tumor immunology. Crit. Rev. Oncog. 1996; 7: 433–456
   PubMed Web of Science ®Google Scholar
• Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 1996; 26: 2671–2679
   PubMed Web of Science ®Google Scholar
• Bogen B., Dembic Z., Weiss S. Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO 1993; 12: 357–363
   PubMed Web of Science ®Google Scholar
• Vyth-Dreese F.A., Dellemijn T.A., van Oostveen J.W., Feltkamp C.A., Hekman A. Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells. Blood 1995; 85: 2802–2812
   PubMed Web of Science ®Google Scholar
• Shamash J., Davies D.C., Salam A., Rohatiner A.Z., Young B.D., Lister T.A. Induction of CD80 expression in low-grade B cell lymphoma–a potential immunotherapeutic target. Leukemia 1995; 9: 1349–1352
   PubMed Web of Science ®Google Scholar
• Dorfman D.M., Schultze J.L., Shahsafaei A., Michalak S., Gribben J.G., Freeman G.J., Pinkus G.S., Nadler L.M. In Vivo Expression of B7–1 and B7–2 on Follicular Lymphoma is Not Sufficient to Induce Significant T Cell Proferation But is Sufficient to Prevent T Cell Anergy In Vitro. Blood 1997; 90: 4297–4306
   PubMed Web of Science ®Google Scholar
• Blay J.Y., Burdin N., Rousset F., Lenoir G., Biron P., Philip T., Banchereau J., Favrot M.C. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169–2174
   PubMed Web of Science ®Google Scholar
• Kopper L., Ladanyi A., Mihalik R., Nagy P. Loss of transforming growth factor beta 1 regulatory activity in human non Hodgkin lymphomas. Antican. Res. 1994; 14: 119–122
   PubMed Web of Science ®Google Scholar
• Bost K.L., Bieligk S.C., Jaffe B.M. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J. Immunol. 1995; 154: 718–729
   PubMed Web of Science ®Google Scholar
• Schultze J.L., Michalak S., Seamon M.J., Gribben J.G., Nadler L.M. CD40 Activated Follicular Lymphoma Cells Are Resistant to And Can Overcome Generalized T Cell Unresponsiveness Induced by IL-10 and TGFβ1. Blood 1996; 88(Suppl)
   PubMed Web of Science ®Google Scholar
• Zinkernagel R.M. Immunology taught by viruses. Science 1996; 271: 173–178
   PubMed Web of Science ®Google Scholar
• Nikolic B., Sykes M. Bone marrow chimerism and transplantation tolerance. Curr. Opin. Immunol. 1997; 9: 634–640
   PubMed Web of Science ®Google Scholar
• Ohashi P.S., Oehen S., Buerki K., Pircher H., Ohashi C.T., Odermatt B., Malissen B., Zinkernagel R.M., Hengartner H. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65: 305–317
   PubMed Web of Science ®Google Scholar
• von Herrath M., Holz A. Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM. J. Autoimmun. 1997; 10: 231–238
   PubMed Web of Science ®Google Scholar
• Von Herrath M.G., Guerder S., Lewicki H., Flavell R.A., Oldstone M.B. Coexpression of B7–1 and viral (“self”) transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 1995; 3: 727–738
   PubMed Web of Science ®Google Scholar
• Von Herrath M.G., Oldstone M.B. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 1997; 185: 531–539
   PubMed Web of Science ®Google Scholar
• Schwartz R.H. A Cell Culture Model for T Lymphocyte Clonal Anergy. Science 1990; 248: 1349–1356
   PubMed Web of Science ®Google Scholar
• Gimmi C.D., Freeman G.J., Gribben J.G., Sugita K., Freedman A.S., Morimoto C., Nadler L.M. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete intesleukin 2. Proc. Natl. Acad. Sci. USA 1991; 88: 6575–6579
   PubMed Web of Science ®Google Scholar
• Gimmi C.D., Freeman G.J., Gribben J.G., Gray G., Nadler L.M. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 1993; 90: 6586–6590
   PubMed Web of Science ®Google Scholar
• Schwartz R.H. T Cell Anergy. 1993; 62–71, Scientific American
   Google Scholar
• Schwartz R.H. T cell clonal anergy. Curr. Opin. Immunol. 1997; 9: 351–357
   PubMed Web of Science ®Google Scholar
• Sprent J., Webb S.R. Intrathymic and extrathymic clonal deletion of T cells. Curr. Opin. Immunol. 1995; 7: 196–205
   PubMed Web of Science ®Google Scholar
• Goodnow C.C. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad. Sci. USA 1996; 93: 2264–2271
   PubMed Web of Science ®Google Scholar
• Waldmann H., Cobbold S. The use of monoclonal antibodies to achieve immunological tolerance. Immunol. Today 1993; 14: 247–251
   PubMedGoogle Scholar
• Cobbold S.P., Adams E., Marshall S.E., Davies J.D., Waldmann H. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol. Rev. 1996; 149: 5–33
   PubMed Web of Science ®Google Scholar
• Weiner H.L., Friedman A., Miller A., Khoury S.J., al-Sabbagh A., Santos L., Sayegh M., Nussenblatt R.B., Trentham D.E., Hafler D.A. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 1994; 12: 809–837
   PubMed Web of Science ®Google Scholar
• Strober W., Kelsall B., Fuss I., Marth T., Ludviksson B., Ehrhardt R., Neurath M. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol. Today 1997; 18: 61–64
   PubMedGoogle Scholar
• Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 1997; 20: 165–177
   PubMed Web of Science ®Google Scholar
• Groux H., Bigler M., de Vries J.E., Roncarolo M.G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 1996; 184: 19–29
   PubMed Web of Science ®Google Scholar
• Buer J., Lanoue A., Franzke A., Garcia C., von Boehmer H., Sarukhan A. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J. Exp. Med. 1998; 187: 177–183
   PubMed Web of Science ®Google Scholar
• Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E., Romani N., Schuler G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 1996; 184: 741–746
   PubMed Web of Science ®Google Scholar
• Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellstrom I, Hellstrom K.E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 1994; 179: 523–532
   PubMed Web of Science ®Google Scholar
• Johnston J.V., Malacko A.R., Mizuno M.T., McGowan P., Hellstrom I., Hellstrom K.E., Marquardt H., Chen L. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med. 1996; 183: 791–800
   PubMed Web of Science ®Google Scholar
• Wick M., Dubey P., Koeppen H., Siegel C.T., Fields P.E., Chen L., Bluestone J.A., Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 1997; 186: 229–238
   PubMed Web of Science ®Google Scholar
• Huang A.Y., Bruce A.T., Pardoll D.M., Levitsky H.I. Does B7–1 expression confer antigen-presenting cell capacity to tumors in vivo?. J. Exp. Med. 1996; 183: 769–776
   PubMed Web of Science ®Google Scholar
• MacLennan I.C., Gulbranson-Judge A., Toellner K.M., Casamayor-Palleja M., Chan E., Sze D.M., Luther S.A., Orbea H.A. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol. Rev. 1997; 156: 53–66
   PubMed Web of Science ®Google Scholar
• Goodnow C.C. Chance encounters and organized rendezvous. Immunol. Rev. 1997; 156: 5–10
   PubMed Web of Science ®Google Scholar
• Shokat K.M., Goodnow C.C. Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature 1995; 375: 334–338
   PubMed Web of Science ®Google Scholar
• Rathmell J.C., Cooke M.P., Ho W.Y., Grein J., Townsend S.E., Davis M.M., Goodnow C.C. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 1995; 376: 181–184
   PubMed Web of Science ®Google Scholar
• Cyster J.G., Goodnow C.C. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity 1995; 3: 691–701
   PubMed Web of Science ®Google Scholar
• Rathmell J.C., Townsend S.E., Xu J.C., Flavell R.A., Goodnow C.C. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319–329
   PubMed Web of Science ®Google Scholar
• Staveley O.C.K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., Pardoll D., Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 1998; 95: 1178–1183
   PubMed Web of Science ®Google Scholar
• Finke J.H., Zea A.H., Stanley J., Longo D.L., Mizoguchi H., Tubbs R.R., Wiltrout R.H., O'Shea J.J., Kudoh S., Klein E. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993; 53: 5613–5616
   PubMed Web of Science ®Google Scholar
• Massaia M., Attisano C., Beggiato E., Bianchi A., Pileri A. Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br. J. Haematol. 1994; 88: 886–888
   PubMed Web of Science ®Google Scholar
• Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J.L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-imfiltrating T-cells and NK cells of patients with coloractal carcinoma. Cancer Res. 1993; 53: 5610–5612
   PubMed Web of Science ®Google Scholar
• Schultze J.L., Boussiotis V.A., Dorfman D., Cardoso A.A., Seamon M.J., Afonso H.M., Gribben J.G., Nadler L.M. Absence of Anti-Follicular Lymphoma (FL) Specific T Cell Mediated Immunity is Associated With Significant Reduction of T Cell Receptor Zeta Chain And Granzyme B Expression. Blood 1995; 86(Suppl)1073
   Google Scholar
• Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T., Tubbs R.B., Finke J. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol. 1995; 155: 1382–1392
   PubMed Web of Science ®Google Scholar
• Guarini A., Riera L., Cignetti A., Montacchini L., Massaia M., Foa R. Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T- cell receptor associated signal transduction molecules. Blood 1997; 89: 212–218
   PubMed Web of Science ®Google Scholar
• Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795–1798
   PubMed Web of Science ®Google Scholar
• Salvadori S., Gansbacher B., Pizzimenti A.M., Zier K.S. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J. Immunol. 1994; 153: 5176–5182
   PubMed Web of Science ®Google Scholar
• Salvadori S., Zier K. Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2. J. Immunol. 1996; 156: 2927–2932
   PubMed Web of Science ®Google Scholar
• Zier K., Gansbacher B., Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol. Today 1996; 17: 39–45
   PubMedGoogle Scholar
• Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu. Rev. Immunol. 1993; 11: 165–190
   PubMed Web of Science ®Google Scholar
• Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X.F., Shimizu J, Fujiwara H., Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 1991; 146: 1077–1082
   PubMed Web of Science ®Google Scholar
• De Waal Malefyt R., Yssel H., de Vries J.E. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J. Immunol. 1993; 150: 4754–4765
   PubMed Web of Science ®Google Scholar
• Becker J.C., Czerny C., Brocker E.B. Maintenance of clonal anergy by endogenously produced IL-10. Inn. Immunol. 1994; 6: 1605–1612
   Web of Science ®Google Scholar
• Holter W., Kalthoff F.S., Pickl W.F., Ebner C., Majdic O., Kraft D., Knapp W. Transforming growth factor-beta inhibits IL-4 and IFN-gamma production by stimulated human T cells. Int. Immunol. 1994; 6: 469–475
   PubMed Web of Science ®Google Scholar
• Kurt R.A., Park J.A., Panelli M.C., Schluter S.F., Marchalonis J.J., Carolus B., Akporiaye E.T. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities. J. Immunol. 1995; 154: 3969–3974
   PubMed Web of Science ®Google Scholar
• De Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A.F., Johnson C.K., Kastelein R., Yssel H., de Vries J. E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen- specific human T cell proliferation by diminishing the antigen- presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991; 174: 915–924
   PubMed Web of Science ®Google Scholar
• Grabbe S., Bruvers S., Granstein R.D. Effects of immunomodulatory cytokines on the presentation of tumor-associated antigens by epidermal Langerhans cells. J. Invest. Dermatol. 1992; 99: 66S–68S
   PubMed Web of Science ®Google Scholar
• Oswald I.P., Gazzinelli R.T., Sher A., James S.L. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J. Immunol. 1992; 148: 3578–3582
   PubMed Web of Science ®Google Scholar
• Bogdan C., Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. N.Y. Acad. Sci. 1993; 685: 713–739
   PubMed Web of Science ®Google Scholar
• Ding L., Linsley P.S., Huang L.Y., Germain R.N., Shevach E.M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression. J. Immunol. 1993; 151: 1224–1234
   PubMed Web of Science ®Google Scholar
• Maeda H., Kuwahara H., Ichimura Y., Ohtsuki M., Kurakata S., Shiraishi A. TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 1995; 155: 4926–4932
   PubMed Web of Science ®Google Scholar
• Skeen M.J., Miller M.A., Shinnick T.M., Ziegler H.K. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 1996; 156: 1196–1206
   PubMed Web of Science ®Google Scholar
• Schultze J.L., Seamon M.J., Michalak S., Gribben J.G., Nadler L.M. Autologous Tumor Infiltrating T Cells Cytotoxic For Follicular Lymphoma Cells Can Be Expanded In Vitro. Blood 1997; 89: 3806–3816
   PubMed Web of Science ®Google Scholar
• Lassila O., Vainio O., Matzinger P. Can B cells turn on virgin T cells?. Nature 1988; 334: 253–255
   PubMed Web of Science ®Google Scholar
• Ho W.Y., Cooke M.P., Goodnow C.C., Davis M.M. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J. Exp. Med. 1994; 179: 1539–1549
   PubMed Web of Science ®Google Scholar
• Rammensee H.G. Maintenance of self tolerance in CD4+ T lymphocytes by antigen presentation on resting B cells–a hypothesis. Bone Marrow Transplant 1991; 1: 26–28, 7 Suppl :–
   Google Scholar
• Eynon E.E., Parker D.C. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med. 1992; 175: 131–138
   PubMed Web of Science ®Google Scholar
• Gilbert K.M., Weigle W.O. Tolerogenicity of Resting and Activated B Cells. J. Exp. Med. 1994; 179: 249–258
   PubMed Web of Science ®Google Scholar
• Croft M., Bradley L.M., Swain S.L. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J. Immunol. 1994; 152: 2675–2685
   PubMed Web of Science ®Google Scholar
• Dubey C., Croft M. Accessory molecule regulation of naive CD4 T cell activation. Immunol. Res. 1996; 15: 114–125
   PubMed Web of Science ®Google Scholar
• Schultze J.L., Michalak S., Lowne J., Wong A., Gilleece M.H., Gribben J.G., Nadler L.M. Human Non-germinal center B cell IL-12 production is primarily regulated by T cell signals CD40L, IFN- and IL-10: Role of B cells in the maintenance of T cell responses
   Google Scholar
• Flamand V., Sornasse T., Thielemans K., Demanet C., Bakkus M., Bazin H., Tielemans F., Leo O., Urbain J., Moser M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 1994; 24: 605–610
   PubMed Web of Science ®Google Scholar
• Stevenson F.K., Zhu D., King C.A., Ashworth L.J., Kumar S., Hawkins R.E. Idiotype DNA Vaccines Against B-cell Lymphoma. Immunol. Rev. 1995; 145: 211–228
   PubMed Web of Science ®Google Scholar
• Syrengelas A.D., Chen T.T., Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 1996; 2: 1038–1041
   PubMed Web of Science ®Google Scholar
• Luna-Fineman S., Lee J.E., Wesley P.K., Clayberger C., Krensky A.M. Human Cytotoxic T-Lymphocytes Specific for Autologous Follicular Lymphoma Recognize Immunoglobulin in a Major Histocompatibility Complex Restricted Fashion. Cancer 1992; 70: 2181–2186
   PubMed Web of Science ®Google Scholar
• Wen Y.J., Lim S.H. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur. J. Immunol. 1997; 27: 1043–1047
   PubMed Web of Science ®Google Scholar